- Home
- TXG vs JANX Comparison
TXG vs JANX Comparison
Compare TXG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- JANX
- Stock Information
- Founded
- TXG 2012
- JANX 2017
- Country
- TXG United States
- JANX United States
- Employees
- TXG N/A
- JANX N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- TXG Industrials
- JANX Health Care
- Exchange
- TXG Nasdaq
- JANX Nasdaq
- Market Cap
- TXG 1.7B
- JANX 1.4B
- IPO Year
- TXG 2019
- JANX 2021
- Fundamental
- Price
- TXG $13.36
- JANX $25.11
- Analyst Decision
- TXG Buy
- JANX Strong Buy
- Analyst Count
- TXG 11
- JANX 8
- Target Price
- TXG $13.41
- JANX $90.63
- AVG Volume (30 Days)
- TXG 3.6M
- JANX 876.9K
- Earning Date
- TXG 08-07-2025
- JANX 08-07-2025
- Dividend Yield
- TXG N/A
- JANX N/A
- EPS Growth
- TXG N/A
- JANX N/A
- EPS
- TXG N/A
- JANX N/A
- Revenue
- TXG $644,466,000.00
- JANX $439,000.00
- Revenue This Year
- TXG N/A
- JANX N/A
- Revenue Next Year
- TXG $5.60
- JANX $1,470.83
- P/E Ratio
- TXG N/A
- JANX N/A
- Revenue Growth
- TXG 2.02
- JANX N/A
- 52 Week Low
- TXG $6.78
- JANX $21.97
- 52 Week High
- TXG $24.76
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- TXG 55.08
- JANX 53.07
- Support Level
- TXG $12.85
- JANX $23.96
- Resistance Level
- TXG $14.22
- JANX $25.93
- Average True Range (ATR)
- TXG 0.94
- JANX 1.55
- MACD
- TXG -0.09
- JANX 0.08
- Stochastic Oscillator
- TXG 52.02
- JANX 69.31
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.